VV119 is named as an intervention in 4 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 1. The lead sponsor is Vigonvita Life Sciences. The most-studied condition is Schizophrenia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119
NCT06504290 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 1 | Recruiting | Vigonvita Life Sciences | China |
|
Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers
NCT07240636 · ClinicalTrials.gov ↗ · Healthy Volunteers
|
Phase 1 | Recruiting | Vigonvita Life Sciences | China |
|
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
NCT07703956 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 2 | Not yet open | Vigonvita Life Sciences | China |
|
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
NCT06105151 · ClinicalTrials.gov ↗ · Schizophrenia
|
Phase 1 | Active, closed | Vigonvita Life Sciences | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Vigonvita Life Sciences | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 2 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name VV119 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 4 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Vigonvita Life Sciences. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how VV119 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how VV119 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists VV119 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.